Treatment Plans

Important Medication Info:
FDA-approved medications such as Mounjaro® and Zepbound™ are proprietary to Eli Lilly and Company™, while Saxenda®, Victoza®, Wegovy®, and Ozempic® are proprietary to Novo Nordisk™. This website is not affiliated with, endorsed by, or associated with these companies or their products.

Invigor Medical does not supply FDA-approved branded medications. Instead, compounded GLP-1 + GIP alternatives may be prescribed when clinically appropriate and legally permissible. These compounded medications are prepared by licensed 503A pharmacies in accordance with the Federal Food, Drug, and Cosmetic Act.

Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or manufacturing quality. They may be prescribed when commercially available options are unsuitable for an individual’s medical needs, but they have not been evaluated by the FDA to confirm safety or efficacy for any specific use.

Important Safety Information for GLP-1 + GIP Treatments

Compounded medications are legally prescribed under federal law but are not FDA-approved and have not undergone FDA review for safety, effectiveness, or manufacturing quality. The GLP-1 + GIP treatment available through Invigor Medical is prescribed following an individualized medical evaluation by a licensed clinician.

WARNING: Risk of Thyroid C-Cell Tumors
In animal studies, GLP-1 receptor agonists have been associated with thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is not known whether these effects occur in humans. Inform your healthcare provider if you experience neck swelling, hoarseness, difficulty swallowing, or shortness of breath. GLP-1 + GIP treatments should not be used by individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Do not use GLP-1 + GIP treatments if:

• You or a family member have a history of MTC or MEN 2.
• You have been diagnosed with type 1 diabetes, pancreatitis, or severe gastrointestinal disease such as gastroparesis.
• You have a known allergy to GLP-1 or GIP medications or their components.
• You have a history of suicidal thoughts or behaviors.

Warnings and Precautions:

• Pancreatitis: Stop treatment immediately if severe abdominal pain occurs.
• Gallbladder Disease: Gallstones and related issues may occur; monitor for symptoms.
• Hypoglycemia: Risk may increase when used with insulin or insulin secretagogues.
• Kidney Injury: Monitor renal function in patients with dehydration or persistent gastrointestinal effects.
• Mood Changes: Discontinue and consult your provider if you experience depression or suicidal thoughts.

Pregnancy and Reproductive Health:
GLP-1 + GIP medications may cause harm to a fetus and should not be used during pregnancy or by individuals planning to become pregnant. Discontinue at least two months before a planned pregnancy.

Common Side Effects:
Nausea, vomiting, diarrhea, constipation, abdominal discomfort, fatigue, and headache are the most commonly reported side effects.

Drug Interactions:
GLP-1 + GIP treatments may slow gastric emptying and alter the absorption of oral medications. Consult your healthcare provider for guidance on timing and dosage adjustments.